News
Press Releases
Press Releases
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the ...
accessibility optionsAccessibility
Text Size
A
A